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Novelty Statement 
 
- Neonatal hypoglycaemia is a common complication of type 1 diabetes pregnancy.  
- We found that 15% of term and 40% of preterm infants had clinically relevant 
neonatal hypoglycaemia requiring treatment with intravenous dextrose.  
- Modest differences in continuous glucose monitoring (CGM) time-in-target (5-7% 
increase) and HbA1c (4 mmol/mol [0.4%] decrease) during the second and third 
trimesters are associated with lower risk of neonatal hypoglycaemia.  
- Clinicians should focus on improving maternal glucose control thereby reducing fetal 
hyperinsulinemia during the second and third trimesters to reduce the risk of neonatal 
hypoglycaemia. 
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Abstract 
 
Aims: To examine the relationship between maternal glycaemic control and risk of neonatal 
hypoglycaemia using conventional and continuous glucose monitoring (CGM) metrics in the 
Continuous Glucose Monitoring in Type 1 Diabetes Pregnancy Trial (CONCEPTT) participants. 
Methods: A secondary analysis of CONCEPTT involving 225 pregnant women and their 
liveborn infants. Antenatal glycaemia was assessed at 12, 24 and 34 weeks gestation. Intrapartum 
glycaemia was assessed by CGM measures 24 hours prior to delivery. The primary outcome was 
neonatal hypoglycaemia defined as glucose concentration <2.6 mmol/L and requiring 
intravenous dextrose.  
Results: Neonatal hypoglycaemia occurred in 57/225 (25.3%) infants; 21 (15%) term and 36 
(40%) preterm neonates. During the second and third trimesters, mothers of infants with  
neonatal hypoglycaemia had higher HbA1c (487 [6.6±0.6] vs 45  7 [6.20.6]; p=0.0009 and 
50  7 [6.7±0.6] vs 46  7 [ 6.3±0.6]; p=0.0001) and lower CGM time-in-range (45.9% vs 
53.0%; p=0.004 and 60.1% vs 65.7%; p=0.03). Neonates with hypoglycaemia had higher cord 
blood C-peptide (1416 [834, 2757] vs 662 [417, 1086] pmol/L; p<0.00001), birthweight >97.7th 
centile (63.2% vs 33.9%; p<0.0001) and skinfold thickness (p≤0.02). Intrapartum CGM was 
available for 33 participants, with no differences between mothers of neonates with and without 
hypoglycaemia.  
Conclusions: Modest increments in CGM time-in-target (5-7% increase) during the second and 
third trimesters are associated with reduced risk for neonatal hypoglycaemia. While more 
intrapartum CGM data are needed, the higher birthweight and skinfold measures associated with 
neonatal hypoglycaemia, suggest that risk is related to fetal hyperinsulinemia preceding the 
immediate intrapartum period.  
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Introduction  
Neonatal hypoglycaemia is a common complication in pregnancies associated with maternal 
diabetes (1). In the short term, neonatal hypoglycaemia requires careful monitoring and may 
require treatment such as intravenous dextrose and/or admission to the neonatal intensive care 
unit (NICU), which incurs substantial healthcare costs. This leads to maternal and infant 
separation, with implications for breastfeeding initiation and even transient hypoglycaemia has 
been associated with longer-term neurodevelopmental impairment into childhood (2).  
 
Type 1 diabetes is a well-established risk factor for neonatal hypoglycaemia (3). Theoretically, 
limiting maternal intrapartum hyperglycaemia reduces the risk of neonatal hypoglycaemia by 
preventing an acute rise in fetal insulin secretion before birth. The Joint British Diabetes 
Societies, National Institute for Health and Clinical Excellence (NICE) and Canadian guidelines 
recommend tight intrapartum glucose targets (4.0 to 7.0 mmol/L) during labour and delivery (4-
6). However, there are insufficient high quality data confirming an association between maternal 
intrapartum glucose control and neonatal hypoglycaemia.  
 
The Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study demonstrated strong, 
continuous associations of maternal glucose levels at 24-32 weeks with neonatal hypoglycaemia.  
The HAPO investigators also demonstrated that birthweight >90th centile and higher percentage 
of body fat were associated with increased risk of neonatal hypoglycaemia. Maternal 
hyperglycaemia throughout pregnancy may be of greater importance than short duration 
intrapartum glucose control. The staff administering complex insulin regimens in labour and 
delivery units may have limited diabetes training, so the potential for neonatal benefit must also 
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be balanced against the demands on patients and healthcare teams and risk of maternal 
hypoglycaemia (1, 7-9).  
 
CONCEPTT (Continuous Glucose Monitoring in Type 1 Diabetes Pregnancy Trial) was a 
multicentre trial, which randomised women to real-time continuous glucose monitoring (CGM) 
or standard capillary glucose monitoring (10). It described significantly less neonatal 
hypoglycaemia in infants of women randomised to CGM compared to standard glucose 
monitoring however, a detailed analysis of the relative importance of intrapartum and antenatal 
glucose was not performed.  
 
No studies have examined the relationship between neonatal hypoglycaemia and both maternal 
antepartum and intrapartum glycaemic control using CGM. Our aim was to examine the 
relationship between maternal glycemic control and risk of neonatal hypoglycaemia using 
conventional and CGM metrics in women with type 1 diabetes. A secondary objective was to 
explore the associations between maternal glycaemia and birthweight percentile, neonatal 
anthropometry measures and fetal hyperinsulinemia assessed by cord blood C-peptide.  
 
Participants and Methods 
Study design and population  
This was a cohort study including all participants in CONCEPTT who had a live birth (n=225). 
The details of CONCEPTT have been previously published (10). In brief, CONCEPTT was a 
multicentre randomised control trial of real-time CGM in pregnant women or women planning 
pregnancy. Eligible women with type 1 diabetes who were either <14 weeks pregnant 
6 
 
(pregnancy trial) or planning pregnancy (planning pregnancy trial) were randomised to CGM or 
capillary glucose monitoring. Women randomised to capillary glucose monitoring had masked 
CGM for 6 days at baseline, 24 and 34 weeks gestation. Intrapartum use of CGM was not part of 
the clinical study protocol, therefore glucose monitoring during labour and delivery, was 
determined by participants and their local healthcare teams.  
 
Definitions and outcomes measures   
Antepartum glycaemic control was assessed using CGM in the first trimester (before 13 weeks 
and 6 days in the pregnancy trial and at 12 weeks gestation in the planning pregnancy trial), 24 
and 34 weeks gestation as per the CONCEPTT protocol. The intrapartum period was defined as 
the 24 hours prior to delivery. This definition of intrapartum glycaemic control was based on 
published data (11, 12) and agreed prior to data analysis. Only participants with at least 12 hours 
of CGM data before delivery were included. Continuous glucose monitoring measures (mean 
glucose, time-in-target, time-above and below-target and glycemic variability measures (SD, 
CV)) during the 24 hours were assessed. Target range both antepartum and intrapartum was 
defined as 3.5 to 7.8 mmol/L.  
 
The primary outcome of interest was clinical neonatal hypoglycaemia defined as having a 
documented glucose concentration of <2.6 mmol/L and requiring treatment with IV dextrose 
within the first 48 hours. Neonatal hypoglycaemia was treated as per local practice across the 31 
sites. Fetal hyperinsulinemia was assessed by cord blood C-peptide, with samples centrifuged 
immediately after birth, kept on ice and stored at -80°C within 2-hours following delivery. 
Plasma C-peptide concentration was measured within one run of a solid-phase, competitive 
7 
 
chemiluminescent immunoassay (intraassay and interassay coefficient of variation of <6%; 
DynaCare, Brampton, Ontario, Canada). For analysis, both the absolute C-peptide measurements 
as well as the categorical variable of > or 90th centile in the Hyperglycemia and Adverse 
Pregnancy Outcomes (HAPO) study were used (13). Fetal anthropometric measures (triceps, sub 
scapular, biceps and suprailiac skin-folds) were performed using calibrated equipment within 72 
hours of birth by trained research staff. Large for gestational age was defined as >90th centile 
and extreme large for gestational age was defined as >97.7th centile using Gestation Related 
Optimal Weight (GROW) software (14).  
 
Statistical analysis  
Continuous data were compared using t-tests or by the Mann-Whitney test and categorical data 
were compared using chi-square tests. Univariate logistic regression was used to screen for 
potential associations between neonatal hypoglycaemia and variables identified as clinically 
important. Multiple logistic regression was carried out using variables identified in these 
univariate analyses. In cases where variables were highly correlated (e.g., most measures of 
maternal glycaemia), the variable with the strongest association and/or those available at time of 
delivery was included in the final model. We assessed for effect modification by preterm 
delivery using a likelihood-ratio test and a stratified analysis was performed when modification 
was identified. Additionally, adjustment for potential confounders including smoking, diabetes 
duration and education level was performed using multiple logistic regression. Results are 
presented as OR (95% confidence intervals [CI]). All analyses were performed using STATA 
(Stata Corp. LP, College Station, TX, Version 14.1). A two-sided p-value of <0.05 was 
considered statistically significant.  
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Results 
Two-hundred and twenty-five CONCEPTT participants had live births and were included in this 
cohort. Of these, 200 women participated in the pregnancy trial and 25 in the planning pregnancy 
trial.  
 
Neonatal hypoglycaemia occurred in 57 (25.3%) of infants (43 and 14 infants in the pregnancy 
and planning pregnancy trial, respectively). Maternal and neonatal characteristics of those with 
and without neonatal hypoglycaemia are shown in Table 1. Mothers of neonates with neonatal 
hypoglycaemia were more likely to use insulin pump therapy. Neonates with hypoglycaemia 
were more likely to be delivered by caesarean section, preterm, admitted to NICU and less likely 
to be exclusively breastfed at discharge. They had higher customised birthweight percentile, and 
higher rates of large and extreme large for gestational age.  
 
Antepartum glycaemic control  
There were no differences in HbA1c or any CGM measures during the first trimester. However, 
in both the second and third trimesters, mothers of infants with neonatal hypoglycaemia had 
suboptimal glucose control with higher HbA1c levels, less time spent in the target glucose range, 
and more time-above-target both at 24 and at 34 weeks gestation.  
 
Intrapartum glycaemic control  
Intrapartum CGM data were available for only 33 of the 225 women included (n=29 real-time 
CGM and n=4 masked CGM). There were no differences in neonatal hypoglycaemia, preterm 
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delivery, birthweight centile, HbA1c or pump use, in women who continued CGM intrapartum 
compared to those who did not (data not presented). However, mothers who used intrapartum 
CGM were older (33.4 vs 31.2 years; p=0.009) and more likely to be randomised to CGM than 
to capillary glucose monitoring (87.9 vs 12.1%; p<0.0001). 
 
There were no significant differences in any CGM measures during the 24 hours prior to delivery 
between mothers of neonates with and without hypoglycaemia (Table 2). Specifically mothers of 
infants with neonatal hypoglycaemia had comparable mean glucose and last glucose prior to 
delivery. Mothers of infants with neonatal hypoglycaemia spent 76% time in target, in the 24 
hours prior to delivery which while numerically lower than mothers without neonatal 
hypoglycaemia (82%), was not statistically different (p=0.82). There was minimal 
hypoglycaemia in both groups and no difference in glucose variability (SD and CV) measures.  
 
Neonatal hypoglycaemia, adiposity and hyperinsulinemia  
Skinfold measurements were available in 150 infants and cord blood C-peptide levels were 
available in 143 cases. Neonates with hypoglycaemia had significantly higher adiposity by 
skinfold thickness measurements (Table 3). Neonates with hypoglycaemia also had evidence of 
hyperinsulinemia with significantly higher cord blood C-peptide levels (median [IQR] 1416 
[834, 2757] vs 662 [417, 1086]; p<0.00001). They also had a significantly higher proportion 
with cord blood C-peptides >90th centile (13).  
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Cord blood C-peptide was higher in preterm neonates, large and extreme large for gestational 
age neonates and if antenatal steroids were given as well as in neonates born in UK, Canada, 
Ireland or the United States compared to those born in Spain or Italy (Table S1).  
 
Cord blood C-peptide was lower in participants who achieved in target glycaemic control in the 
second and third trimesters, defined as a HbA1c <6.5%, compared to those that did not (Table 
S1). Post hoc analyses revealed no difference in cord C-peptide levels of women who were 
overweight compared to women with normal weight in early pregnancy. There was also no 
difference in cord C-peptide levels in women with excessive compared to appropriate gestational 
weight gain defined by the Institute of Medicine guidelines (15). Neonates with cord blood C-
peptide >90th centile by HAPO criteria had significantly higher adiposity as assessed by skinfold 
thickness than those ≤90th centile by HAPO (sum of 4 skin folds (triceps, subscapular, biceps, 
flank) 24.5 ± 5.7 vs 19.2 ± 3.8 mm respectively; p<0.00001).  
 
Logistic regression analysis  
Univariate logistic regression identified gestational age at delivery, large and extreme large for 
gestational age, antenatal glycaemia (2nd and 3rd trimester HbA1c and CGM measures), insulin 
pump use, caesarean delivery, and cord blood C-peptide as being significantly associated with 
neonatal hypoglycaemia (Table S2).  
 
When developing the model, preterm delivery was a significant effect modifier in the 
relationship between extreme large for gestational age and neonatal hypoglycaemia in the overall 
model (p-value for interaction term 0.02). In term neonates, extreme large for gestational age 
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(adjusted OR 6.1 [95% CI 1.8, 20.7]; p=0.004) and 3rd trimester HbA1c (adjusted OR 3.5 [95% 
CI 1.3, 9.7]; p=0.02) were significantly associated with increased odds of neonatal 
hypoglycaemia in both the unadjusted analysis and the analysis adjusted for smoking, diabetes 
duration and education level (Table 4). However, in preterm neonates, neither extreme large for 
gestational age (adjusted OR 1.2 [95% CI 0.5, 3.1]; p=0.65) nor 3rd trimester HbA1c (adjusted 
OR 1.2 [95% CI 0.6, 2.4]; p=0.67) were significantly associated with increased odds of neonatal 
hypoglycaemia.  
 
Discussion 
Maternal antenatal glucose control, as measured by HbA1c and CGM during the second and 
third trimesters, is associated with clinically relevant neonatal hypoglycaemia. Taken together 
with the CONCEPTT trial results, our data suggest that modest improvements in maternal 
glycaemia, in the order of a 0.4% decrease in HbA1c or a 5-7% increased CGM time in target 
range, is associated with reductions in neonatal hypoglycaemia. We did not find differences in 
intrapartum glycaemic control, although statistical power was limited by the small numbers of 
women who continued using CGM until delivery.  
 
The mechanism of neonatal hypoglycaemia appears to be fetal hyperinsulinemia as demonstrated 
by the high concentration of cord blood C-peptide, markers of infant size (birthweight centile) 
and infant adiposity (skinfold measurements) in neonates with hypoglycaemia. Interestingly, 
participants from Mediterranean countries (Spain and Italy) had significantly lower C-peptide 
concentrations. We hypothesize that this reflects the lower rates of large for gestational age in 
Spain and Italy, as well as a combination of glycemic control, genetic, dietary and environmental 
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factors (10). The HAPO investigators previously demonstrated that the odds of neonatal 
hypoglycaemia increased in a graded way with increasing cord blood C-peptide levels (13). They 
also noted birthweight >90th centile and higher percentage of body fat were associated with 
higher C-peptide levels. Our study demonstrated that achieving target HbA1c at 24 and 34 weeks 
gestation is associated with lower C-peptide levels in type 1 diabetes pregnancies, suggesting 
that it is more than just the immediate intrapartum period that contributes to fetal 
hyperinsulinemia.  
 
Like previous studies, our analysis highlights the association between antenatal glycaemic 
control and increased risk of neonatal hypoglycaemia (16, 17). However, our study includes 
detailed CGM measures during pregnancy, suggesting that interventions to improve second and 
third trimester glucose control may be more impactful for reducing the risk of neonatal 
hypoglycaemia, than intrapartum interventions. In the pregnancy trial in CONCEPTT, CGM led 
to a 50% reduction in the odds ratio for neonatal hypoglycaemia (15 vs 28%; p=0.03). Both 
women with and without neonatal hypoglycaemia spent more time in target range in the 
intrapartum period (76.0 and 81.8% respectively) compared to 34 weeks gestation (60.1 and 
65.7% respectively). This is consistent with the closed-loop studies in pregnancy which 
demonstrate a higher time in target in the intrapartum period compared to earlier in pregnancy 
(11, 18, 19).Whist insulin pump use during pregnancy was associated with increased risk of 
neonatal hypoglycaemia, there was no increased risk associated with continuing pump therapy 
during labour and delivery, consistent with recent data (20). Given the limited hyperglycaemia in 
the intrapartum period, it seems unlikely that closed-loop insulin delivery would reduce 
intrapartum hyperglycaemia, although it may be useful for limiting maternal hypoglycaemia, be 
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more resource efficient than intravenous insulin regimens and preferable for women to manage 
their own diabetes (11).  
 
We also found extreme large for gestational age was associated with a 6-fold increased odds of 
neonatal hypoglycaemia in term neonates. This increased risk of neonatal hypoglycaemia seen 
with larger neonates is also consistent with previous literature (21-23). It is important that 
clinicians are aware of the compounding effect of infant size when managing term babies on the 
post-natal ward. Interestingly, we found that preterm birth was a significant effect modifier in the 
relationship between extreme large for gestational age and neonatal hypoglycaemia. We 
postulate that preterm delivery alone is associated with such a high risk of neonatal 
hypoglycaemia, that additional risk factors do not play as large a role. Future research should 
consider whether routine administration of buccal mucosa dextrose could reduce the risk of 
neonatal hypoglycaemia in high risk preterm type 1 diabetes offspring (24). 
 
The literature supporting the importance of intrapartum control is inconsistent (1). Only a few 
studies have used CGM to characterise intrapartum glycaemic control (11, 12, 22, 25). A pilot 
study evaluating closed-loop during labour and delivery (n=27 participants) found comparable 
intrapartum glycaemia (82% time in target range) to CONCEPTT participants without neonatal 
hypoglycaemia, also with no between group differences according to the presence or absence of 
neonatal hypoglycaemia (11). Another study (n=16 participants) examining the feasibility of 
paired maternal intrapartum CGM and newborn CGM, found a lower but not statistically 
significant, intrapartum CGM time-in-target in mothers of neonates requiring intravenous 
glucose (65% vs 90%; p=0.16) (12). Cordua et al. found that time spent >7.0 mmol/L was higher 
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in mothers of neonates with hypoglycaemia, but their study lacked details of antepartum 
glycaemia as measured by CGM (22). Stenninger et al. reported a higher mean glucose 
concentration two hours before delivery in 15 women with type 1, type 2 and gestational diabetes 
(25). It is implausible that the markers of fetal hyperinsulinemia and neonatal adiposity in our 
study could have been attributed to two hours of suboptimal glycaemia. Large, high quality, 
randomised controlled trials of strict vs more relaxed intrapartum targets would be needed to 
determine if the benefits of strict glycemic control during this period outweigh the risks in 
women with type 1 diabetes.  
 
Our study has several strengths. It is a large, multicentre, well characterised cohort of women 
with type 1 diabetes with detailed information regarding glycaemic control as assessed by both 
HbA1c and CGM. The data were prospectively collected and rigorously evaluated with 
standardised central laboratory HbA1c and C-peptide measurements and a robust, clinically 
meaningful definition of neonatal hypoglycaemia. This is the largest contemporary cohort of 
women with type 1 diabetes, in whom cord blood C-peptide and detailed neonatal anthropometry 
measures are available.  
 
We also acknowledge its limitations, most notably, the small number of women who used CGM 
during labour and delivery. Given our sample size, we cannot exclude that intrapartum 
glycaemic control, may be associated with neonatal hypoglycaemia. We estimate that to detect a 
clinically relevant 5% increase CGM time-in-target range would require a sample size of 350 
participants. Due to our definition of neonatal hypoglycaemia, we may also have underestimated 
the number of babies who were managed supportively with increased feeds or formula top up 
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feeds. Additionally, this is an observational analysis and while we adjusted and evaluated for 
potential confounders, residual confounding may exist. This is particularly relevant for the 
apparent association between antenatal insulin pump therapy and neonatal hypoglycaemia which 
is confounded by differences in maternal characteristics and glucose control between women 
using pumps or multiple daily injections (26). Finally, given the strong correlations between 
HbA1c and other markers of glycaemia, the findings presented in Table 4 should not be 
interpreted to mean that it is only HbA1c that is associated with neonatal glycemia.   
 
It is clear that antepartum glycaemic control in the second and third trimesters is potentially 
modifiable and that even modest improvements are associated with decreased risk of neonatal 
hypoglycaemia. Efforts should focus on helping more women with type 1 diabetes to improve 
glycaemic control throughout pregnancy so that the consequences of preterm birth and neonatal 
adiposity can be minimised. The high risk of neonatal hypoglycaemia in infants delivered before 
37 weeks, has important implication in terms of resource utilization, separation of infant mother 
pairs, and the long-term impact of neonatal hypoglycaemia into childhood. Further research into 
understanding the mechanisms, management and longer term consequences of neonatal 
hypoglycaemia, especially among preterm infants and extreme large for gestational age term 
infants of mothers with suboptimal glucose control is required.  
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Table 1: Maternal and Neonatal Characteristics of Offspring with and without Neonatal 
Hypoglycaemia   
Variable Neonatal Hypoglycaemia No Neonatal Hypoglycaemia p-value  
 n=57 n=168  
Maternal Characteristics 
Age (years) 30.5  4.6 31.7  4.5 0.09 
Duration of diabetes (years) 17.2  7.6  16.3  7.7 0.79 
Diabetes complications* 11 (19) 47 (28) 0.20 
Insulin pump use  35 (61) 75 (45)  0.03 
Insulin pump during labour & delivery  13 (23) 33 (20) 0.61 
Education (post-secondary) 42 (75) 132 (79) 0.58 
Smoking during pregnancy 4 (7) 16 (10) 0.57 
Primiparous 21 (37) 68 (40) 0.63 
BMI (kg/m2) 25.7  4.5 25.8  4.6  0.83 
Pre-conception folic acid 29 (51) 87 (52) 0.91 
Antenatal steroids  20 (35) 38 (23) 0.06 
Antenatal Glycaemia** 
First Trimester      
HbA1c (%) 6.9  0.6 6.9  0.6 0.74 
HbA1c (mmol/mol) 52  6 52  7 0.74 
At target HbA1c*** 18 (35) 47 (30) 0.55 
Time in target range (%) 49.3  12.8 52.4  13.1 0.12 
Time above target (%) 42.3  14.0 39.1  14.3 0.14 
Second Trimester  
HbA1c (%) 6.6  0.6 6.2  0.6 0.0009 
HbA1c (mmol/mol) 48  7 45  7 0.0009 
At target HbA1c 32 (58) 113 (72) 0.07 
Time in target range (%) 45.9  14.5 53.0  15.1 0.004 
Time above target (%) 49.8  16.4 41.6  16.6 0.002 
Third Trimester   
HbA1c (%) 6.7  0.6 6.3  0.6 0.0001 
HbA1c (mmol/mol) 50  7  46  7 0.0001 
At target HbA1c  18 (35) 105 (70) <0.0001 
Time in target range (%) 60.1  15.7  65.7  14.1  0.03 
Time above target (%) 35.5  16.5 29.0  14.0  0.01 
Neonatal Characteristics 
Caesarean delivery  47 (83) 108 (64) 0.01 
Gestational age (weeks) 36.2  1.7  37.2  1.6 0.0002 
Preterm birth (<37 weeks)  36 (63) 53 (32) <0.0001 
NICU admission  51 (90) 32 (19) <0.0001 
Birthweight (grams) 3705  819 3543  659  0.13 
Birthweight centile  89.1  21.5 80.3  26.2 0.02 
SGA <10th centile  1 (2) 3 (2) 1.0 
LGA >90th centile  42 (74) 97 (58) 0.03 
Extreme LGA >97.7th centile  36 (63) 57 (34) <0.0001 
Exclusive breastfeeding at discharge  18 (32)  83 (50) 0.02 
Data are presented as n (percentages) or means  standard deviation. *Defined as any retinopathy, neuropathy or 
nephropathy; **HbA1c available for n=52 to 55 mothers of infants with and n=156 to 158 without neonatal 
hypoglycaemia; For CGM data n=43 to 57 for mothers of infants with and n=133 to 168 without neonatal 
hypoglycaemia; ***Target HbA1c defined as <6.5% (48 mmol/mol); SGA, small for gestational age; LGA large for 
gestational age; NICU, neonatal intensive care unit. 
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Table 2: Intrapartum Continuous Glucose Monitoring Measures of Maternal Glycaemic Control 
by Offspring with and without Neonatal Hypoglycaemia 
 
Glucose Parameter  Neonatal Hypoglycaemia No Neonatal Hypoglycaemia p-value 
 n=9 n=24  
Time in target range (%) 76.0 (71.4, 83.0) 81.8 (58.8, 92.1) 0.82  
Time above target range (%) 14.8 (11.5, 24.36) 16.8 (5.4, 33.2) 0.89 
Time below target range (%) 0 (0, 2.8) 0 (0, 2.3) 0.67 
Last blood glucose 
concentration prior to delivery 
(mmol/l) 
5.7 (5.2, 7.9) 5.6 (5.3, 8.3) 0.89 
Mean blood glucose 
concentration in labour and 
delivery (mmol/l) 
6.4 (5.6, 7.0) 6.4 (5.8, 7.0) 0.81 
Standard deviation (mmol/l) 1.4 (0.8, 1.8) 1.7 (1.1, 2.3) 0.11 
Coefficient of variation (%) 22.2 (14.8, 32.3) 26.1 (20.4, 31.1) 0.28 
Data are presented as medians (interquartile range); Target defined as 3.5-7.8 mmol/L. 
Intrapartum use of CGM was not required by the CONCEPTT study protocol, therefore glucose monitoring during 
labour and delivery, was determined by participants and local healthcare teams. Data were available for 33 
CONCEPTT participants (29 real-time CGM, 4 masked CGM). 
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Table 3: Neonatal Adiposity and Cord Blood C-peptide Concentration in Offspring with and 
without Neonatal Hypoglycaemia 
 
Variable Neonatal Hypoglycaemia No Neonatal Hypoglycaemia p-value  
Skinfold measurements in 
mm 
n=27 n=123  
Triceps  6.8  1.9 5.8  1.7 0.004 
Biceps  5.8  1.4 4.9  1.4 0.005 
Subscapular  6.5  1.5 5.7  1.6 0.02 
Flank (suprailiac)  6.0  1.9 5.1  1.8 0.02 
 n=38 n=102  
Cord blood C-peptide 
concentration (pmol/L) 
1416 (834, 2757)_ 662 (417, 1086) <0.0001 
Cord blood C-peptide 
concentration>566 pmol/L \ 
33 (87) 59 (58) 0.001 
Data are presented as n (percentages), means  standard deviation, or median (interquartile range); Skinfold 
measurements were available for 150 neonates; Cord blood C-peptides were available for n=143 neonates. Cord c-
peptide >566 pmol/L is based on >90th percentile value (>1.7 ug/L) in the HAPO study 
 
  
23 
 
Table 4: Results of Multivariable Logistic Regression for Neonatal Hypoglycaemia  
 
 Unadjusted Adjusted* 
 Odds ratio (95%  CI) p-value Odds ratio (95%  CI) p-value 
Term Neonates**     
Extreme LGA 6.2 (1.8, 21.0) 0.003 6.1 (1.8, 20.7) 0.004 
3rd trimester HbA1c (per 1%) 3.5 (1.4, 9.0)  0.01 3.5 (1.3, 9.7) 0.02 
Preterm Neonates      
Extreme LGA 1.3 (0.5, 3.2) 0.57 1.2 (0.5, 3.1) 0.65 
3rd trimester HbA1c (per 1%) 1.2 (0.6, 2.5) 0.58 1.2 (0.6, 2.4) 0.67 
*Adjusted model including extreme LGA, 3rd trimester HbA1c and smoking, diabetes duration, and education level 
stratified by preterm delivery; **Analysis stratified by preterm delivery (p-value for interaction term =0.02); LGA, 
large for gestational age 
 
 
 
 
 
